StockData

Cellectis vs Protalix BioTherapeutics

CLLS and PLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CLLS and PLX compare

Cellectis grew revenue faster over the last twelve months (75.8% versus 30.1% for Protalix BioTherapeutics).

Protalix BioTherapeutics keeps more of each dollar of sales as profit, with a net margin of 23.5% compared with −92.7% at Cellectis.

Protalix BioTherapeutics scores higher on the StockData Score (16 against 3 for Cellectis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCLLSPLX
Size and price
Market cap–$244M
Share price$1.04$3.03
Change, 1 year−70.9%57.0%
Change, 5 years−88.0%206%
Beta (5Y)2.471.33
Employees229226
StockData Score
Total score316 (better)
Valuation score04 (better)
Growth score22
Performance score14 (better)
Health score06 (better)
Dividend score00
Valuation
P/E–13.2×
P/S–3.0×
P/B–3.4×
EV/EBITDA–9.3×
P/FCF–31.8×
FCF yield–3.1%
Fair value–$5.40
Margin of safety–43.9%
Growth
Revenue growth (TTM)75.8% (better)30.1%
Revenue growth, 5Y average7.4% (better)−3.5%
Net income growth (TTM)–202%
EPS growth (TTM)–475%
Profitability
Gross margin100% (better)69.2%
Operating margin−45.3%28.9% (better)
Net margin−92.7%23.5% (better)
FCF margin−57.2%9.5% (better)
Return on equity−97.8%31.2% (better)
Return on invested capital−122%49.5% (better)
Financial health
Debt / equity–0.00
Interest coverage−0.6×–
Current ratio–2.94
Altman Z-score–5.85
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions9.4%17.9%
Held by insiders53.4%3.8%
Insider net buying, 12 months–$101K
Short interest, % of float–4.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.